- Conditions
- Prediabetes, Type 2 Diabetes
- Interventions
- Vitamin D (Cholecalciferol), Placebo
- Dietary Supplement · Other
- Lead sponsor
- Tufts Medical Center
- Other
- Eligibility
- 30 Years and older
- Enrollment
- 2,423 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2018
- U.S. locations
- 25
- States / cities
- Phoenix, Arizona • Los Angeles, California • Palo Alto, California + 20 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1801–1824
of 7,459
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Select Advanced Solid Tumors
- Interventions
- Brenetafusp, Brenetafusp and pembrolizumab, Brenetafusp and chemotherapy, Brenetafusp and monoclonal antibodies and chemotherapy, Brenetafusp and tebentafusp, Brenetafusp and bevacizumab, Brenetafusp and kinase inhibitors
- Drug
- Lead sponsor
- Immunocore Ltd
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 410 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2027
- U.S. locations
- 22
- States / cities
- La Jolla, California • Los Angeles, California • Sacramento, California + 17 more
- Conditions
- Migraine
- Interventions
- Placebo ZNS, ZNS
- Drug
- Lead sponsor
- Impax Laboratories, LLC
- Industry
- Eligibility
- 6 Years to 11 Years
- Enrollment
- 374 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2020
- U.S. locations
- 47
- States / cities
- Phoenix, Arizona • Little Rock, Arkansas • Anaheim, California + 38 more
- Conditions
- Dyskinesia, Levodopa Induced Dyskinesia (LID), Parkinson's Disease (PD)
- Interventions
- ADS-5102
- Drug
- Lead sponsor
- Adamas Pharmaceuticals, Inc.
- Industry
- Eligibility
- 30 Years to 85 Years
- Enrollment
- 223 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2018
- U.S. locations
- 54
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 46 more
- Conditions
- Impotence
- Interventions
- Viagra (Sildenafil Citrate) 100 mg
- Drug
- Lead sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
- Industry
- Eligibility
- 18 Years to 70 Years · Male only
- Enrollment
- 355 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2006
- U.S. locations
- 33
- States / cities
- Birmingham, Alabama • Homewood, Alabama • Hoover, Alabama + 30 more
- Conditions
- Diffuse Large B-Cell Lymphoma, Follicular Lymphoma, Marginal Zone Lymphoma, Mantle Cell Lymphoma, Small Lymphocytic Lymphoma
- Interventions
- Ublituximab, Umbralisib, Bendamustine
- Biological · Drug
- Lead sponsor
- TG Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 710 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2022
- U.S. locations
- 111
- States / cities
- Birmingham, Alabama • Huntsville, Alabama • Chandler, Arizona + 97 more
- Conditions
- HIV Infections
- Interventions
- Romidepsin, Placebo for Romidepsin
- Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 59 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2018
- U.S. locations
- 10
- States / cities
- Birmingham, Alabama • Los Angeles, California • Aurora, Colorado + 7 more
- Conditions
- Cytomegalovirus Infections, HIV Infections
- Interventions
- Valganciclovir
- Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 13 Years and older
- Enrollment
- 350 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2000 – 2006
- U.S. locations
- 56
- States / cities
- Birmingham, Alabama • Los Angeles, California • Palo Alto, California + 33 more
- Conditions
- Partially Edentulous Maxilla or Mandible
- Interventions
- PrimeTaper EV
- Device
- Lead sponsor
- McGuire Institute
- Industry
- Eligibility
- 25 Years and older
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2026
- U.S. locations
- 8
- States / cities
- Aurora, Colorado • Broomfield, Colorado • Oakbrook Terrace, Illinois + 5 more
- Conditions
- Bladder Cancer
- Interventions
- Sacituzumab tirumotecan, Vinflunine, Docetaxel, Paclitaxel, Rescue medications for sacituzumab tirumotecan, Rescue medications for chemotherapy
- Biological · Drug
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 590 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2030
- U.S. locations
- 23
- States / cities
- Newport Beach, California • Aurora, Colorado • Highlands Ranch, Colorado + 19 more
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- High-dose colesevelam, Low-dose colesevelam
- Drug
- Lead sponsor
- Daiichi Sankyo
- Industry
- Eligibility
- 10 Years to 17 Years
- Enrollment
- 236 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2020
- U.S. locations
- 24
- States / cities
- Tucson, Arizona • Little Rock, Arkansas • Los Angeles, California + 20 more
- Conditions
- Recurrent and Refractory Solid Tumors
- Interventions
- Lenvatinib, Everolimus
- Drug
- Lead sponsor
- Eisai Inc.
- Industry
- Eligibility
- 2 Years to 21 Years
- Enrollment
- 64 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2022
- U.S. locations
- 47
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Loma Linda, California + 42 more
- Conditions
- Spinal Muscular Atrophy, Neuromuscular Diseases, SMA
- Interventions
- taldefgrobep alfa, Placebo
- Drug
- Lead sponsor
- Biohaven Pharmaceuticals, Inc.
- Industry
- Eligibility
- 4 Years to 21 Years
- Enrollment
- 269 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 30
- States / cities
- Phoenix, Arizona • La Jolla, California • Los Angeles, California + 27 more
- Conditions
- Venous Malformation, Lymphatic Malformation, Venolymphatic Malformation
- Interventions
- VT30
- Drug
- Lead sponsor
- Venthera, Inc., a BridgeBio company
- Industry
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2022
- U.S. locations
- 15
- States / cities
- Phoenix, Arizona • Little Rock, Arkansas • Palo Alto, California + 12 more
- Conditions
- Hematopoietic Cell Transplantation (HCT)
- Interventions
- Mindful Music Listening (MML)
- Other
- Lead sponsor
- University of Colorado, Denver
- Other
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 35 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 1
- States / cities
- Aurora, Colorado
- Conditions
- Peritoneal Dialysis Complication
- Interventions
- Isolation of peritoneal mesothelial cells
- Diagnostic Test
- Lead sponsor
- University of Colorado, Denver
- Other
- Eligibility
- 18 Years to 90 Years
- Enrollment
- 22 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2019
- U.S. locations
- 1
- States / cities
- Aurora, Colorado
- Conditions
- Acute Lymphoblastic Leukemia, Adult B Lymphoblastic Lymphoma, Ann Arbor Stage I B Lymphoblastic Lymphoma, Ann Arbor Stage II B Lymphoblastic Lymphoma, Childhood B Acute Lymphoblastic Leukemia, Childhood B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1, Childhood B Lymphoblastic Lymphoma, Down Syndrome, Hypodiploid B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Positive
- Interventions
- Cyclophosphamide, Cytarabine, Dexamethasone, Doxorubicin Hydrochloride, Laboratory Biomarker Analysis, Leucovorin Calcium, Mercaptopurine, Methotrexate, Pegaspargase, Quality-of-Life Assessment, Questionnaire Administration, Thioguanine, Vincristine Sulfate
- Drug · Other
- Lead sponsor
- Children's Oncology Group
- Network
- Eligibility
- 1 Year to 30 Years
- Enrollment
- 9,350 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2026
- U.S. locations
- 213
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 153 more
- Conditions
- Bronchiolitis
- Interventions
- De-implementation Strategy for Bronchiolitis
- Behavioral
- Lead sponsor
- University of Colorado, Denver
- Other
- Eligibility
- 1 Month to 80 Years
- Enrollment
- 20,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2024
- U.S. locations
- 3
- States / cities
- Aurora, Colorado • Columbus, Ohio • Seattle, Washington
- Conditions
- Colorectal Neoplasms
- Interventions
- sunitinib, mFOLFOX6, bevacizumab
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 191 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2011
- U.S. locations
- 81
- States / cities
- Fairhope, Alabama • Mobile, Alabama • Chandler, Arizona + 65 more
- Conditions
- Cytokine Storm (Covid-19)
- Interventions
- Ruxolitinib, Placebo
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 432 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020
- U.S. locations
- 11
- States / cities
- Fullerton, California • Aurora, Colorado • Denver, Colorado + 8 more
- Conditions
- Hepatocellular Cancer, Liver Cancer
- Interventions
- OMP-54F28 with Sorafenib
- Drug
- Lead sponsor
- OncoMed Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years to 90 Years
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2017
- U.S. locations
- 6
- States / cities
- Los Angeles, California • Aurora, Colorado • Indianapolis, Indiana + 3 more
- Conditions
- Methicillin-Resistant Staphylococcus Aureus
- Interventions
- Not listed
- Lead sponsor
- University of Colorado, Denver
- Other
- Eligibility
- Up to 89 Years
- Enrollment
- 4,518 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2010
- U.S. locations
- 1
- States / cities
- Aurora, Colorado
- Conditions
- Carcinoma, Squamous Cell
- Interventions
- Pembrolizumab, Placebo
- Biological · Drug
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 450 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2026
- U.S. locations
- 30
- States / cities
- Mobile, Alabama • Duarte, California • La Jolla, California + 26 more
- Conditions
- Rheumatoid Arthritis
- Interventions
- N/A (Observational Study)
- Other
- Lead sponsor
- University of Colorado, Denver
- Other
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 340 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2026
- U.S. locations
- 1
- States / cities
- Aurora, Colorado